Medical technology company Implanet has secured the US Food and Drug Adminstration’s 510(k) clearance and CE mark approval for its new Jazz Claw hybrid implant.

The new Jazz Claw implant has been designed to treat complex degenerative pathologies in adults (kyphosis), a growing indication driven by the aging population.

Implanet said the Jazz Claw will replace traditional hook and screw fixation systems as it provides autostable posterior fixation.

The implant’s autostable characteristics will also help to treat adolescent scoliosis with hybrid fixation.

Implanet product development and manufacturing director Régis Le Couedic said: "Jazz Claw is Implanet’s response to the complex issue of securing the top of constructs in adolescent scoliosis and adult degenerative deformities."

Implanet CEO Ludovic Lastennet said: "Jazz Claw is a major new component of our Jazz Band platform, an implant that supplements our product offering for major deformities and meets a major market demand.

"In this respect, it should rapidly be adopted by our partners, whether specializing in pediatric or adult degenerative indications."

Based in Bordeaux of France, Implanet manufactures implants for orthopedic surgery.